Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity
about
Parenteral adjuvant activities of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infectionCholera toxin: a paradigm of a multifunctional proteinProlonged colonization of mice by Vibrio cholerae El Tor O1 depends on accessory toxinsSeparable effector T cell populations specialized for B cell help or tissue inflammation.The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen.Phagocytic antigen processing and effects of microbial products on antigen processing and T-cell responses.Mucosal adjuvant properties of mutant LT-IIa and LT-IIb enterotoxins that exhibit altered ganglioside-binding activities.Salmonella enterica serovar enteritidis ghosts carrying the Escherichia coli heat-labile enterotoxin B subunit are capable of inducing enhanced protective immune responses.Inhibition of class II major histocompatibility complex antigen processing by Escherichia coli heat-labile enterotoxin requires an enzymatically active A subunitCholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in immunomodulation by type I and type II heat-labile enterotoxins.Mucosal immunity and tolerance: relevance to vaccine development.Rotavirus 2/6 viruslike particles administered intranasally with cholera toxin, Escherichia coli heat-labile toxin (LT), and LT-R192G induce protection from rotavirus challenge.Protective mucosal immunity to ocular herpes simplex virus type 1 infection in mice by using Escherichia coli heat-labile enterotoxin B subunit as an adjuvant.Nontoxic Shiga toxin derivatives from Escherichia coli possess adjuvant activity for the augmentation of antigen-specific immune responses via dendritic cell activationPolymeric display of immunogenic epitopes from herpes simplex virus and transmissible gastroenteritis virus surface proteins on an enteroadherent fimbria.Cholera toxin B subunit activates arachidonic acid metabolismMucosal vaccination with recombinantly attenuated staphylococcal enterotoxin B and protection in a murine model.Escherichia coli heat-labile enterotoxin B subunit is a more potent mucosal adjuvant than its vlosely related homologue, the B subunit of cholera toxin.Outer membrane vesicles of Porphyromonas gingivalis elicit a mucosal immune response.The LTR72 mutant of heat-labile enterotoxin of Escherichia coli enhances the ability of peptide antigens to elicit CD4(+) T cells and secrete gamma interferon after coapplication onto bare skinGenetically manipulated bacterial toxin as a new generation mucosal adjuvant.Mucosal immune network in the gut for the control of infectious diseases.A revisit of mucosal IgA immunity and oral tolerance.Evaluation of an intranasal virosomal vaccine against respiratory syncytial virus in mice: effect of TLR2 and NOD2 ligands on induction of systemic and mucosal immune responses.Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infectionMechanisms of inflammasome activation by Vibrio cholerae secreted toxins vary with strain biotype.Effects of cholera toxin on innate and adaptive immunity and its application as an immunomodulatory agent.Molecular cloning of an apoptosis-inducing protein, pierisin, from cabbage butterfly: possible involvement of ADP-ribosylation in its activityA second generation of double mutant cholera toxin adjuvants: enhanced immunity without intracellular trafficking.Nasal Administration of Cholera Toxin as a Mucosal Adjuvant Damages the Olfactory System in Mice.Induction of cell signaling events by the cholera toxin B subunit in antigen-presenting cellsThe catalytic A1 domains of cholera toxin and heat-labile enterotoxin are potent DNA adjuvants that evoke mixed Th1/Th17 cellular immune responsesNasal vaccination with the 40-kilodalton outer membrane protein of Porphyromonas gingivalis and a nontoxic chimeric enterotoxin adjuvant induces long-term protective immunity with reduced levels of immunoglobulin E antibodies.A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity.Cholera toxin and Escherichia coli heat-labile enterotoxin, but not their nontoxic counterparts, improve the antigen-presenting cell function of human B lymphocytesDendritic cell-targeting DNA-based mucosal adjuvants for the development of mucosal vaccinesUse of translational fusion of the MrpH fimbrial adhesin-binding domain with the cholera toxin A2 domain, coexpressed with the cholera toxin B subunit, as an intranasal vaccine to prevent experimental urinary tract infection by Proteus mirabilisImmunomodulation of gut-associated lymphoid tissue: current perspectives.Bioadhesive delivery systems for mucosal vaccine delivery.Progress towards a needle-free hepatitis B vaccine.
P2860
Q24548763-0E94E3BF-DCEE-40C4-949D-20F84B05766FQ24598726-0C603A08-5811-4226-A161-79C840D11AFCQ30363424-A8208001-F468-4BEA-A5F6-F6C2673CB6FBQ33182376-8F7B57FD-0F24-4190-9EBC-2A7227F9C172Q33451335-C401A2FE-D3B8-4D26-90B5-256B5F5AF319Q33683408-685ECA54-61F3-4C07-9931-E66B44BD828FQ33715999-E6B6300E-77BB-4DA2-9CD4-5843DB3B24B5Q33743411-AF692C63-583A-469B-B741-1F1D92AB45ABQ33757092-5EE92F96-82BC-4888-859A-28AB8ED2A5A2Q33768109-DEBCECF7-8E70-4210-994D-F66F7BE3FCB2Q33776172-F0AFF814-A1F0-4451-89DC-3087C3E0532BQ33783470-1CAFB5A7-E5F1-457C-A1A6-88863B8D9601Q33837275-4A0A39B0-958F-4795-A296-98034E6EA05AQ33883311-1B4A06D0-1A09-4DF1-B388-812946BBACF0Q33997509-7FC9D8D5-0F55-4F6F-AAFA-137CE57D9B10Q34000342-0EC9E724-2A36-4AAA-AAFE-7C920DE7CB47Q34006649-2655AA7D-8FA8-4FD5-8D63-C80CE8432B2AQ34007453-810F769A-E479-4B45-B437-AE238CB0E1DDQ34056091-E7277662-C900-4D8D-AFAE-E467DC25472FQ34123358-24905A08-70F5-4122-A6C1-BA3B2BCAB87AQ34184890-4B7AACD5-19CB-4947-8DB9-BC2F88AB7379Q34191806-0A75DB7E-C7A2-4FD2-B454-38C7F68899CFQ34419871-41185C56-12DA-4239-B53A-812B9057D8DBQ34674831-41D9FBF5-2544-487D-B99B-F3323E546240Q35550138-47658721-6863-40B0-AED0-73DACBA4AA82Q35609312-92B2816F-0166-409D-A304-F1377479DF18Q35619878-50F2174A-9BE8-4838-858C-6EA9CD093226Q35626584-6C0FEEE2-6945-44AC-81F5-C11F66122313Q35747402-75AFB08C-6B1D-4F15-8BE0-4D78C65477D8Q35793731-9AF58C8A-133F-4D21-9E3B-AA941F6D5ECCQ35913540-87B83B9D-8885-42C3-9F91-1A20BE659F9CQ36256348-1D0957B7-9F88-4F10-99A6-B4E67126431DQ36710668-7980CFD0-8ABB-47BF-90C4-320A0566BD90Q36770993-637EB2A5-9D76-4BB3-98A3-7939D7DAF4A1Q37191283-97B580AB-1E95-4207-80EB-B6247DAF19B3Q37590337-0ACC7323-5712-4D66-9A82-203569875D90Q37623929-8CC37ADD-AD38-42B1-AFEF-DFB153198D91Q37642859-4218B49E-5894-431D-A0F7-74406F424104Q37805519-1E3F839B-2229-4232-95A4-23B279E453A3Q37810816-063A53A7-8C2C-43E0-AFE3-9DE017ACDD77
P2860
Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
Mutants in the ADP-ribosyltran ...... icity but retain adjuvanticity
@ast
Mutants in the ADP-ribosyltran ...... icity but retain adjuvanticity
@en
type
label
Mutants in the ADP-ribosyltran ...... icity but retain adjuvanticity
@ast
Mutants in the ADP-ribosyltran ...... icity but retain adjuvanticity
@en
prefLabel
Mutants in the ADP-ribosyltran ...... icity but retain adjuvanticity
@ast
Mutants in the ADP-ribosyltran ...... icity but retain adjuvanticity
@en
P2093
P2860
P356
P1476
Mutants in the ADP-ribosyltran ...... icity but retain adjuvanticity
@en
P2093
H Kurazono
J R McGhee
K Fujihashi
M Yamamoto
S Yamamoto
P2860
P304
P356
10.1084/JEM.185.7.1203
P407
P577
1997-04-01T00:00:00Z